In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mimetogen Pharmaceuticals, Inc.

http://www.mimetogen.com/

Latest From Mimetogen Pharmaceuticals, Inc.

Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.

Clinical Trials Business Strategies

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.

Ophthalmic Market Intelligence

Pfizergan Offers Warm Embrace For Pfizer’s Internal And Allergan’s External R&D

Pfizer R&D chief Mikael Dolsten and his counterpart at Allergan, David Nicholson, oversee very different research organizations, but in interviews at the J.P. Morgan Healthcare Conference the two heads of R&D insisted the chasm between their research models is not so vast.

BioPharmaceutical Clinical Trials

Why Pfizer’s R&D Chief Dolsten Is Enthusiastic About Allergan

President-Worldwide R&D Mikael Dolsten talked in an interview at J.P. Morgan about the research opportunities for a combined Pfizer/Allergan – and bridging two different approaches to R&D.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register